Article

Human stem cell trial on hold

The linkurl:Geron Corporation;http://www.geron.com/ linkurl:announced on Tuesday;http://www.geron.com/media/pressview.aspx?id=1187 (August 18) that its stem cell study of spinal cord injury -- the first-ever clinical trial using human embryonic stem cell (hESC)-based therapy -- has been put on hold by the linkurl:US Food and Drug Administration;http://www.fda.gov/ (FDA) pending the review of some newly submitted animal data. Human embryonic stem cellsImage: Wikimedia commons, Nissim Benvenisty

Written byJef Akst
| 2 min read
Save for Later
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
The linkurl:Geron Corporation;http://www.geron.com/ linkurl:announced on Tuesday;http://www.geron.com/media/pressview.aspx?id=1187 (August 18) that its stem cell study of spinal cord injury -- the first-ever clinical trial using human embryonic stem cell (hESC)-based therapy -- has been put on hold by the linkurl:US Food and Drug Administration;http://www.fda.gov/ (FDA) pending the review of some newly submitted animal data.
Human embryonic stem cells
Image: Wikimedia commons,
Nissim Benvenisty
The study, which linkurl:received clearance;http://www.the-scientist.com/blog/display/55353/ on January 23 of this year after a 7 month hold by the FDA, aims to treat patients with severe spinal cord injury by injecting hESC-derived progenitors of neural support tissue into the spinal cord. So far, no patients have received the experimental therapy. Since Geron submitted its Investigational New Drug application to the FDA in March, 2008, the company has continued to pursue animal studies on the therapy (referred to as GRNOPC1), particularly with regard to increasing dosages and applying the therapy to other neurodegenerative diseases. This week's hold from the FDA came shortly after submitting the data from some of this work. Holds on clinical trials are not all that uncommon, especially in cases of novel treatments such as this one, linkurl:points out The Niche,;http://blogs.nature.com/reports/theniche/2009/08/first_embryonic_stemcell_trial.html Nature's stem cell blog: A similar hold was issued by the FDA in February, for example, for a NeuralStem trial on Lou Gehrig's disease. However, given the timing of this hold, it is likely that safety concerns arising from the higher-dosage experiments prompted the move by the FDA, analyst Joseph Pantginis linkurl:told the New York Times.;http://www.nytimes.com/2009/08/19/health/research/19drug.html?_r=2 Geron didn't reply to a call requesting comment yesterday. The company stated in a press release that it "will work closely with the FDA to facilitate their review of the new data and to release the clinical hold."
**__Related stories:__***linkurl:Geron CEO: Q&A;http://www.the-scientist.com/news/display/55379/
[26th January 2009]*linkurl:Right on Geron;http://www.the-scientist.com/blog/display/55354/
[23rd January 2009]*linkurl:FDA OKs stem cell trial;http://www.the-scientist.com/blog/display/55353/
[23rd January 2009]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Join for free today
Already a member? Login Here

Meet the Author

  • Jef Akst

    Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share

Related Research Resources

An illustration of PFAS in the bloodstream.

Uncovering the Harmful Effects of PFAS Exposure on the Human Body

Infographic

An illustration of PFAS bubbles in front of a blue sky with clouds.

PFAS: The Forever Chemicals

Infographic

sartorius logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

Article

Wastewater surveillance conceptual visualization of a water droplet containing different microorganism

Elevating Wastewater Epidemiology with Microfluidics

Webinar

Image of a woman with her hands across her stomach. She has a look of discomfort on her face. There is a blown up image of her stomach next to her and it has colorful butterflies and gut bacteria all swarming within the gut.
November 2025, Issue 1

Why Do We Feel Butterflies in the Stomach?

These fluttering sensations are the brain’s reaction to certain emotions, which can be amplified or soothed by the gut’s own “bugs".

View this Issue

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Olga Anczukow and Ryan Englander discuss how transcriptome splicing affects immune system function in lung cancer.

Long-Read RNA Sequencing Reveals a Regulatory Role for Splicing in Immunotherapy Responses

Pacific Biosciences logo
Research Roundtable: The Evolving World of Spatial Biology

Research Roundtable: The Evolving World of Spatial Biology

Conceptual cartoon image of gene editing technology

Exploring the State of the Art in Gene Editing Techniques

Bio-Rad
Conceptual image of a doctor holding a brain puzzle, representing Alzheimer's disease diagnosis.

Simplifying Early Alzheimer’s Disease Diagnosis with Blood Testing

fujirebio logo

Products

Product News

Labvantage Logo

LabVantage Solutions Awarded $22.3 Million U.S Customs and Border Protection Contract to Deliver Next-Generation Forensic LIMS

The Scientist Placeholder Image

Evosep Unveils Open Innovation Initiative to Expand Standardization in Proteomics

SPT Labtech Logo
OGT logo

OGT expands MRD detection capabilities with new SureSeq Myeloid MRD Plus NGS Panel